These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32499321)

  • 1. USP General Chapter <825> Impact on Nuclear Medicine Technology Practice.
    Hinkle GH
    J Nucl Med Technol; 2020 Jun; 48(2):106-113. PubMed ID: 32499321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mayo Clinic approaches to meet United States Pharmacopeia <797> requirements for facility design and environmental controls of nuclear pharmacy.
    Hung JC; Anderson MM
    J Nucl Med; 2009 Jan; 50(1):156-64. PubMed ID: 19091891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of sterile admixture practices in canadian hospital pharmacies: part 2. More results and discussion.
    Warner T; Nishi C; Checkowski R; Hall KW
    Can J Hosp Pharm; 2009 May; 62(3):192-203. PubMed ID: 22478890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of sterile admixture practices in canadian hospital pharmacies: part 1. Methods and results.
    Warner T; Nishi C; Checkowski R; Hall KW
    Can J Hosp Pharm; 2009 Mar; 62(2):100-11. PubMed ID: 22478875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP <800>: Key Considerations and Changes for Health Systems.
    Sahadeo P; Weber RJ
    Hosp Pharm; 2015 Nov; 50(10):941-949. PubMed ID: 27729683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterile Compounding Pharmacies: States That Do and Do Not Require Compliance With USP <797> Versus FDA 483s.
    Wilson M
    Ther Innov Regul Sci; 2016 May; 50(3):279-303. PubMed ID: 30227076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of commercial nuclear pharmacy in the future practice of nuclear medicine.
    Callahan RJ
    Semin Nucl Med; 1996 Apr; 26(2):85-90. PubMed ID: 8723502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality-Control Analytical Methods: Microbial-Testing Aspects of USP Chapter 797 for Compounded Sterile Preparations.
    Kupiec TC
    Int J Pharm Compd; 2005; 9(1):47-9. PubMed ID: 23924865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifty Years of Radiopharmaceuticals.
    Brugarolas P; Comstock J; Dick DW; Ellmer T; Engle JW; Lapi SE; Liang SH; Parent EE; Kishore Pillarsetty NV; Selivanova S; Sun X; Vavere A; Scott PJH;
    J Nucl Med Technol; 2020 Jun; 48(Suppl 1):34S-39S. PubMed ID: 32605944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy compounding of high-risk level products and patient safety.
    Mullarkey T
    Am J Health Syst Pharm; 2009 Sep; 66(17 Suppl 5):S4-13. PubMed ID: 19710449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacy-led
    Mekoba BC; Turingan EM; Roberts PA; Mason S; Willoughby I; Taylor C; Stivers A; Valgus J
    Am J Health Syst Pharm; 2018 May; 75(10):627-632. PubMed ID: 29650727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strengthening radiopharmacy practice in IAEA Member States.
    Duatti A; Bhonsle U
    Semin Nucl Med; 2013 May; 43(3):188-94. PubMed ID: 23561456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of newly revised sterile medication compounding guidelines USP {797} on allergy vial preparation.
    Lin SY; Houser SM; Gross G; Aaronson D
    Otolaryngol Head Neck Surg; 2008 Jul; 139(1):5-6. PubMed ID: 18585553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of United States Pharmacopeia chapter 797: results of a national survey.
    Candy TA; Schneider PJ; Pedersen CA
    Am J Health Syst Pharm; 2006 Jul; 63(14):1336-43. PubMed ID: 16809754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extemporaneously compounded sterile medications: relevance of new United States pharmacopeial standards to pain clinicians.
    Rusho WJ
    J Pain Palliat Care Pharmacother; 2004; 18(4):69-76. PubMed ID: 15760810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A collaborative effort to comply with USP chapter 797 for compounding sterile preparations for investigational use.
    Formea CM; Weiss WT; McCluskey SV
    Am J Health Syst Pharm; 2008 Jul; 65(13):1266-9. PubMed ID: 18574018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.